Case that could stop half of U.S. abortions set for this Wednesday

 

null / ivanko80/Shutterstock

Washington D.C., Mar 13, 2023 / 14:50 pm (CNA).

The first hearing in what could be the most consequential abortion case since the overturning of Roe v. Wade is set for this Wednesday, March 15.

The Alliance for Hippocratic Medicine (AHM), along with several other medical organizations and doctors, is suing the Federal Drug Administration for its approval and expansion of the abortion drug mifepristone.

On Jan. 3, the FDA changed its policy to allow pharmacies, such as CVS and Walgreens, to sell mifepristone. Previously, the FDA only allowed certified doctors, clinics, and some mail-order pharmacies to dispense the drug. After the FDA’s policy change, any patient with a prescription can obtain mifepristone from her local retail pharmacy.

Represented by the Alliance Defending Freedom (ADF), AHM is alleging that the FDA has been recklessly endangering women and young girls for decades by ignoring its own research and testing standards and continuing to expand its mifepristone approval.

The case is being heard by U.S. Judge Matthew Kacsmaryk for the Northern District of Texas, a Trump appointee.

The Wednesday court date was announced to lawyers involved with the case on Friday.

Kacsmaryk reportedly planned to not announce the hearing date to the public until Tuesday evening and urged attorneys to not disclose the information to avoid any disruptions to the proceedings.

According to the New York Times, Kacsmaryk said that court staff have “faced security issues, including death threats.”

A high-stakes case, if Kacsmaryk rules against the FDA, the administration could be forced to rescind its approval of the drug, bringing its legal distribution to a halt across the country, even in states where abortion remains legal.

Mifepristone is the first of two drugs used in chemical abortions, which account for 53% of all abortions in the country, according to the Guttmacher Institute.

The drug works by cutting off nutrients necessary for a fetus to continue developing. A second drug, misoprostol, is then ingested 24 to 48 hours later and induces contractions that expel the dead unborn child.

Mifepristone was first approved in 2000 and is commonly used throughout the country today.

“The abortion industry loves the chemical abortion regimen because it has such low overhead costs; the mother is the abortionist. The supplier of the lethal chemicals still gets paid, but the mother ingests the pills, expels the baby, and disposes of the body on her own,” California Right to Life director Mary Rose Short told CNA.

According to Short, “the abortion pill regimen [in California] is considered such a basic staple that the Democratic Legislature mandated that all state universities provide abortions in their campus health centers.”

ADF argues that the FDA never conducted thorough tests on mifepristone’s effect on minors, directly harming young girls across the nation who use the drug to this day.

Dr. Ingrid Skop, an OB-GYN and director of medical affairs at the Charlotte Lozier Institute, told CNA in February that “chemical abortion pills are far more dangerous than surgical abortion. They are far more dangerous than the abortion industry has told the American public.”

This is a developing story.


If you value the news and views Catholic World Report provides, please consider donating to support our efforts. Your contribution will help us continue to make CWR available to all readers worldwide for free, without a subscription. Thank you for your generosity!

Click here for more information on donating to CWR. Click here to sign up for our newsletter.


About Catholic News Agency 10303 Articles
Catholic News Agency (www.catholicnewsagency.com)

Be the first to comment

Leave a Reply

Your email address will not be published.

All comments posted at Catholic World Report are moderated. While vigorous debate is welcome and encouraged, please note that in the interest of maintaining a civilized and helpful level of discussion, comments containing obscene language or personal attacks—or those that are deemed by the editors to be needlessly combative or inflammatory—will not be published. Thank you.


*